查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1965362

Omega-3处方药市场－全球产业规模、份额、趋势、机会、预测：按药物类型、应用、分销管道、地区和竞争格局划分，2021-2031年

Omega 3 Prescription Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug type, By Application, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球Omega-3处方药市场预计将从 2025 年的 22.1 亿美元成长到 2031 年的 36.9 亿美元，复合年增长率为 8.92%。

这些药用级製剂由二十碳五烯酸 (EPA) 和二十二碳六烯酸 (DHA) 的纯化乙酯或羧酸组成，主要用于治疗重度高高三酸甘油脂血症。市场成长的主要驱动因素包括全球心血管疾病盛行率的上升以及医疗专业人员越来越多地采用预防性血脂管理策略。此外，人口老化和全球肥胖率上升等人口结构变化也使得人们对有效治疗方案的需求日益增长，进一步推动了对这些受监管药物的需求。

市场概览
预测期 2027-2031
市场规模：2025年 22.1亿美元
市场规模：2031年 36.9亿美元
复合年增长率：2026-2031年 8.92%
成长最快的细分市场 高三酸甘油脂血症节段
最大的市场 北美洲

然而，市场成长面临许多挑战，包括提炼药用级鱼油以满足严格监管标准的供应链复杂性和高成本。这些严格的品质要求往往导致库存短缺和价格波动，进而影响全球产品供应。根据美国环保署（EPA）和国际组织关于DHA Omega-3的数据，2024年全球Omega-3原料总量将达到131,183吨，比上年增加2.5%。同时，市场总值将达到约24亿美元，成长10.2%。

市场驱动因素

推动全球Omega-3处方药市场成长的主要因素是全球心血管疾病和肥胖症发生率的激增。由于高三酸甘油脂血症与超重密切相关，因此有效的药物干预对于降低胰臟炎和心肌梗塞等疾病的风险至关重要。显着的人口趋势进一步加剧了这项需求。根据世界肥胖联盟于2024年3月发布的《2024年世界肥胖地图集》，预计2035年，全球肥胖成年人口将达到15.3亿。这些疾病的高死亡率凸显了血脂管理的重要性，美国心臟协会发布的《2024年心血管和中风统计更新》也支持了这一观点，该报告指出，2021年美国有931,578人死于心血管疾病。

此外，在积极的监管核准推动下，随着患者和医疗保健提供者加速从营养补充剂转向处方治疗，市场正在不断扩张。由于高纯度、经政府批准的製剂具有更高的生物利用度和经证实能降低三酸甘油酯水平的临床疗效，医疗保健专业人员越来越倾向于选择此类製剂​​而非非处方药。这种向药物治疗的转变正在对受监管市场的商业性表现产生显着影响。例如，Amarin公司于2024年10月发布的2024年第三季财报显示，其VAZKEPA在欧洲的销售额环比增长了19%，这表明处方Omega-3疗法正在被主要的国际医疗保健系统迅速采用。

市场挑战

全球Omega-3处方药市场主要受制于复杂的供应链和高昂的生产成本。与合成药物不同，这类药物严重依赖海洋来源的原料，尤其是粗鱼油，而这些原料需要昂贵的大规模精炼製程才能达到药用级纯度要求。这种对自然资源的依赖使得生产商极易受到不可预测的环境条件和严格的捕捞配额的影响，导致价格和供应大幅波动。因此，企业难以维持稳定的库存水平，造成生产瓶颈、供应延迟，并阻碍医疗机构将这些治疗方法用于长期治疗。

近期产业波动凸显了这套原料供应链的脆弱性。根据国际鱼油生产商联合会（IFFO）预测，2024年全球鱼油产量将年增12%，这显示在经历了严重的供不应求短缺之后，市场对气候变迁高度敏感。原物料供应的快速波动迫使生产商承担高昂的避险和仓储营运成本，以确保供应的连续性。这些财务压力最终会波及整个供应链，导致药品价格持续高企，并限制了注重成本的医疗保健系统获得市场进入。

市场趋势

学名药（例如二十碳五烯酸乙酯）的激增从根本上改变了竞争格局。尤其在美国，市场主导地位的丧失导致价格大幅下降。这些低价替代品的进入崩坏了曾经由品牌药主导的市场，迫使现有生产商缩减商业活动，同时透过降价扩大病患的用药管道。这种商品化带来的巨大财务影响在近期主要品牌药的业绩中得到了清楚的体现。根据Amarin公司2024年10月发布的2024年第三季财报，其在美国的旗舰处方药净销售额从去年同期的6,240万美元下降至3,060万美元。这一下滑直接归因于非专利竞争对手市场份额的扩大。

同时，为弥补北美和欧洲市场的饱和，各公司正加速向亚太市场进行策略性商业扩张。这一趋势标誌着企业关注的焦点正从传统的北美和欧洲市场转移，同时，企业也在那些心血管疾病高危险群众多且未接受治疗的国家/地区获得监管部门的核准。中国在这扩张过程中扮演着至关重要的角色，为处方降血脂药物提供了新的患者群体。正如Amarin公司在2024年7月发布的公告《Amarin合作伙伴Edding Farm的VASCEPA在中国当地获得监管核准》中所指出的，中国估计有3.3亿心血管疾病患者，这凸显了该地区在未来行业产生收入的关键作用。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球Omega-3处方药市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依药物类型（Vascepa、Lovaza 等）
    • 依应用（高三酸甘油脂血症，其他）
    • 分销通路（医院药局、零售药局、网路药局）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美Omega-3处方药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲Omega-3处方药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区Omega-3处方药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东及非洲地区Omega-3处方药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲Omega-3处方药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球Omega-3处方药市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Abbott Laboratories Inc
  • Amarin Pharmaceuticals Ireland Ltd.
  • GSK plc（GlaxoSmithKline plc）
  • Natrapharm, Inc.（Patriot Pharmaceutical Corp.）
  • Viatris, Inc.
  • Grupo Ferrer Internacional, SA
  • Camber Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Zydus Group
  • Hikma Pharmaceuticals PLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 24047

The Global Omega 3 Prescription Drugs Market is projected to expand from USD 2.21 billion in 2025 to USD 3.69 billion by 2031, registering a compound annual growth rate of 8.92%. These pharmaceutical-grade formulations, composed of purified ethyl esters or carboxylic acids sourced from eicosapentaenoic and docosahexaenoic acids, are prescribed primarily to treat severe hypertriglyceridemia. Key factors driving market growth include the rising prevalence of cardiovascular conditions worldwide and the growing implementation of preventative lipid management strategies by medical professionals. Furthermore, demographic changes such as an aging global population and increasing obesity rates create a strong need for effective therapeutic options, thereby reinforcing the demand for these regulated medical treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.21 Billion
Market Size 2031USD 3.69 Billion
CAGR 2026-20318.92%
Fastest Growing SegmentHypertriglyceridemia Segment
Largest MarketNorth America

However, market growth faces significant hurdles due to supply chain complications and high production costs involved in refining raw fish oils to strictly regulated pharmaceutical standards. These rigorous quality demands frequently result in stock shortages and fluctuating prices, which subsequently affect global product availability. Data from the Global Organization for EPA and DHA Omega-3s indicates that in 2024, the total global volume of omega-3 ingredients hit 131,183 metric tons, marking a 2.5% increase from the previous year, while the total market value grew by 10.2% to reach roughly $2.4 billion.

Market Driver

The primary forces accelerating the Global Omega 3 Prescription Drugs Market are the surging global rates of cardiovascular disease and obesity. Since elevated triglyceride levels are closely associated with excess body weight, effective pharmaceutical interventions are essential to reduce risks such as pancreatitis and myocardial infarction. This demand is further amplified by significant demographic trends; the World Obesity Federation's 'World Obesity Atlas 2024', released in March 2024, estimates that the global population of adults with obesity will rise to 1.53 billion by 2035. The high mortality rate linked to these conditions emphasizes the critical need for lipid management, a fact highlighted by the American Heart Association's '2024 Heart Disease and Stroke Statistics Update', which noted that cardiovascular disease caused 931,578 deaths in the United States in 2021.

Additionally, the market is growing as patients and providers increasingly transition from dietary supplements to prescription-grade therapies, aided by favorable regulatory endorsements. Medical professionals increasingly prefer high-purity, government-authorized formulations over over-the-counter alternatives because of their superior bioavailability and demonstrated clinical effectiveness in reducing triglyceride levels. This movement toward medicalized treatment is clearly influencing commercial results in regulated markets. For instance, Amarin Corporation's 'Third Quarter 2024 Financial Results' from October 2024 reported a 19% sequential increase in VAZKEPA sales in Europe, demonstrating the rapid adoption of prescription omega-3 therapies within major international healthcare systems.

Market Challenge

The expansion of the Global Omega 3 Prescription Drugs Market is substantially constrained by supply chain intricacies and substantial production costs. In contrast to synthetic medicines, these drugs rely heavily on marine-sourced raw materials, particularly crude fish oil, which necessitates expensive and extensive refinement to meet pharmaceutical-grade purity requirements. This dependence on natural resources subjects manufacturers to significant volatility regarding price and availability, often caused by unpredictable environmental conditions and strict fishing quotas. As a result, companies struggle to maintain stable inventories, causing production bottlenecks that delay supply and deter healthcare providers from depending on these therapies for long-term care.

Recent industry fluctuations emphasize the vulnerability of this raw material supply chain. According to IFFO, cumulative global fish oil production in 2024 was estimated to show a 12% year-on-year increase, a figure that highlights the market's acute sensitivity to climatic events following a period of severe shortage. Such drastic swings in raw material availability compel manufacturers to absorb higher operational costs related to hedging and storage to guarantee continuity. These financial pressures are eventually passed down the supply chain, sustaining high drug prices and restricting market access within cost-conscious healthcare systems.

Market Trends

The competitive environment is being fundamentally altered by the widespread availability of generic icosapent ethyl products, especially in the United States where the loss of market exclusivity has led to sharp price reductions. The entry of these more affordable alternatives has broken the monopoly once held by branded drugs, compelling established manufacturers to shrink their commercial operations while simultaneously expanding patient access through lower prices. The significant financial toll of this commoditization is clear in the recent performance of leading brands; Amarin Corporation's 'Third Quarter 2024 Financial Results' from October 2024 revealed that U.S. net product revenue for its primary prescription drug fell to $30.6 million from $62.4 million in the same period the previous year, a decline directly caused by the growing market share of generic rivals.

Concurrently, companies are accelerating strategic commercial expansion into Asia-Pacific markets to compensate for saturation in Western regions. This trend involves achieving regulatory successes in nations with vast, untreated populations at risk of cardiovascular disease, shifting focus beyond traditional North American and European markets. China has become a pivotal area for this expansion, presenting a substantial new patient base for prescription lipid therapies. As noted in Amarin Corporation's July 2024 announcement titled 'Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA in Mainland China', the country is home to an estimated 330 million patients with cardiovascular disease, highlighting the region's essential role in generating future industry revenue.

Key Market Players

  • Abbott Laboratories Inc
  • Amarin Pharmaceuticals Ireland Ltd.
  • GSK plc (GlaxoSmithKline plc)
  • Natrapharm, Inc. (Patriot Pharmaceutical Corp.)
  • Viatris, Inc.
  • Grupo Ferrer Internacional, S.A.
  • Camber Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Zydus Group
  • Hikma Pharmaceuticals PLC

Report Scope

In this report, the Global Omega 3 Prescription Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Omega 3 Prescription Drugs Market, By Drug type

  • Vascepa
  • Lovaza
  • Others

Omega 3 Prescription Drugs Market, By Application

  • Hypertriglyceridemia
  • Others

Omega 3 Prescription Drugs Market, By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Omega 3 Prescription Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Omega 3 Prescription Drugs Market.

Available Customizations:

Global Omega 3 Prescription Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Omega 3 Prescription Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug type (Vascepa, Lovaza, Others)
    • 5.2.2. By Application (Hypertriglyceridemia, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Omega 3 Prescription Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug type
    • 6.2.2. By Application
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Omega 3 Prescription Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Omega 3 Prescription Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Omega 3 Prescription Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Distribution Channel

7. Europe Omega 3 Prescription Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug type
    • 7.2.2. By Application
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Omega 3 Prescription Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Omega 3 Prescription Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Omega 3 Prescription Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Omega 3 Prescription Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Omega 3 Prescription Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Omega 3 Prescription Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug type
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Omega 3 Prescription Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Omega 3 Prescription Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Omega 3 Prescription Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Omega 3 Prescription Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Omega 3 Prescription Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Omega 3 Prescription Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug type
    • 9.2.2. By Application
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Omega 3 Prescription Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Omega 3 Prescription Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Omega 3 Prescription Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Distribution Channel

10. South America Omega 3 Prescription Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug type
    • 10.2.2. By Application
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Omega 3 Prescription Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Omega 3 Prescription Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Omega 3 Prescription Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Omega 3 Prescription Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amarin Pharmaceuticals Ireland Ltd.
  • 15.3. GSK plc (GlaxoSmithKline plc)
  • 15.4. Natrapharm, Inc. (Patriot Pharmaceutical Corp.)
  • 15.5. Viatris, Inc.
  • 15.6. Grupo Ferrer Internacional, S.A.
  • 15.7. Camber Pharmaceuticals, Inc.
  • 15.8. Dr. Reddy's Laboratories Ltd.
  • 15.9. Zydus Group
  • 15.10. Hikma Pharmaceuticals PLC

16. Strategic Recommendations

17. About Us & Disclaimer